ulcerative colitis

Also found in: Thesaurus, Medical, Acronyms, Encyclopedia, Wikipedia.

Related to ulcerative colitis: diverticulitis, Crohn's disease, irritable bowel syndrome

ulcerative colitis

A form of inflammatory bowel disease affecting the colon and rectum, characterized by abdominal pain, diarrhea, and rectal bleeding.

American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.

ThesaurusAntonymsRelated WordsSynonymsLegend:

Switch to new thesaurus

Noun 1. ulcerative colitis - a serious chronic inflammatory disease of the large intestine and rectum characterized by recurrent episodes of abdominal pain and fever and chills and profuse diarrhea

colitis, inflammatory bowel disease - inflammation of the colon

Mentioned in ?

References in periodicals archive ?

The CONDUCT study is evaluating the first-in-class TLR9 agonist cobitolimod and includes 213 patients with left-sided moderate to severe active ulcerative colitis not responding to conventional therapy.

InDex Pharmaceuticals meets primary endpoint in the phase IIb study CONDUCT with cobitolimod in ulcerative colitis

The agency also said that the approved use of tofacitinib for ulcerative colitis will be restricted to certain patients who do not respond to, or who have severe side effects with, certain other medicines.

FDA: Blood Clot, Death Risk Up With Higher Dose of Tofacitinib; Increased risk seen with 10 mg dose of tofacitinib used for treating ulcerative colitis

Ulcerative colitis and Crohn's disease are long-term conditions that involve inflammation of the gut.

What is inflammatory bowel disease (IBD)?

According to the company, cobitolimod is a Toll-like receptor 9 (TLR9) agonist, which can provide an anti-inflammatory effect locally in the large intestine, which may induce mucosal healing and relief of the clinical symptoms in ulcerative colitis.

InDex Pharmaceuticals admits last patient in Phase IIb Study CONDUCT evaluating cobitolimod for ulcerative colitis

The data set excluded patients with indeterminate colitis or who underwent colectomy for ulcerative colitis. From 1990 through 1993, only 10% of patients with IBD were prescribed opioids, vs.

Opioids linked to mortality in inflammatory bowel disease

Tofacitinib is an oral, small-molecular Janus kinase inhibitor approved in the United States for treating moderate to severe ulcerative colitis, as well as rheumatoid and psoriatic arthritis.

Tofacitinib raised herpes zoster risk in ulcerative colitis

Ulcerative colitis affects the large intestine and causes irritation and swelling called inflammation whereas Crohn's disease is a chronic inflammatory bowel disease (IBD) characterised by inflammation that responds to tissue injury ultimately causing redness, swelling, and pain.

Inflammatory bowel disease during childhood linked to higher cancer rates: Study

Theravance plans to initiate a Phase IIb/in adaptive design study in ulcerative colitis with TD-1473 and is planning to initiate a Phase n study in Crohn's disease this year.

Theravance, J&J Ink 1ドルB Deal for Inflammatory Drug

Inflammatory damage from ulcerative colitis causes ulcers inside the lining of the large intestine (rectum and colon).

Understanding Inflammatory Bowel Diseases: Ulcerative colitis and Crohn's disease are both IBDs, but there are important differences

The present study shows that a brief cycle of GMA in patients with steroid-dependent, azathioprine-intolerant or resistant moderate ulcerative colitis is associated with a 36% steroid-free clinical remission and a 15% clinical response after 12 months of follow-up.

Granulocyte-Monocyte Apheresis in Steroid-Dependent, Azathioprine-Intolerant/Resistant Moderate Ulcerative Colitis: A Prospective Multicenter Study

This study further investigated the effects of Breg cells and Th17 cells on ulcerative colitis by determining peripheral blood Breg cells, Th17 cells, and related molecules in patients with ulcerative colitis and provided theoretical basis for targeted therapy and prognosis of ulcerative colitis.

Decreased Breg/Th17 Ratio Improved the Prognosis of Patients with Ulcerative Colitis